Tag: Major depressive disorder

First approved by the FDA in 2002 for schizophrenia, Abilify (aripiprazole) has since expanded its list of approved uses to help manage several different mental health conditions. Understanding **what mental illness does Abilify treat?** is crucial for patients and caregivers considering this atypical antipsychotic.

In 2021, an estimated 21 million adults in the United States had at least one major depressive episode [1.14.1]. When considering treatment, a common question is: **Is Abilify better than Effexor?** These medications work differently and treat different, sometimes overlapping, conditions.

In the United States, over 2 million patients have been prescribed Trintellix for Major Depressive Disorder (MDD) [1.7.2]. A common question that arises is, **Is Trintellix an SSRI?** The answer is no; it belongs to a distinct class of antidepressants [1.2.1].

In 2023, bupropion was the seventeenth most commonly prescribed medication in the United States, with over 30 million prescriptions [1.2.3]. So, **what drug class is bupropion?** It is an atypical antidepressant belonging to the norepinephrine-dopamine reuptake inhibitor (NDRI) class [1.2.3].

In clinical trials for major depressive disorder, up to 14% of patients taking Rexulti experienced akathisia (restlessness) [1.14.3]. For many users, a key question is: **do side effects of Rexulti go away?** The answer varies depending on the specific side effect.

According to a 2020 review published in *Psychiatry Online*, quetiapine is one of the most commonly prescribed drugs for bipolar patients and is often used as an adjunct to antidepressants. Choosing which antidepressant works best with quetiapine is not a simple decision, as it depends on the specific condition being treated, potential drug interactions, and the patient's individual tolerance and side effect profile.

First approved by the FDA in 1989 for treating Parkinson's disease, selegiline's primary classification is as a monoamine oxidase inhibitor, specifically a selective and irreversible inhibitor of the MAO-B enzyme at low doses. This makes knowing **what is the medication classification of selegiline?** essential for comprehending its multifaceted clinical applications in both neurological and psychiatric contexts.

In 2025, an estimated 18.3% of U.S. adults are currently experiencing or being treated for depression [1.8.1]. For many, a key question is affordability, which leads them to ask: **Has Viibryd gone generic?** The answer is yes, offering a more accessible treatment option.

In 2015, approximately 7.7 million prescriptions for oral aripiprazole were dispensed in the U.S.. When deciding on an atypical antipsychotic, a common question is: What's better, aripiprazole or Quetiapine? The answer depends heavily on individual patient needs and side effect sensitivities.

Between 2015 and 2018, about 13.2% of U.S. adults reported using antidepressants [1.9.2]. If you've been prescribed Viibryd (vilazodone), a primary concern is understanding the answer to: **how long does it take Viibryd to kick in?**